Virologic and clinical features of patients infected with HIV-1 and HTLV-II in relationship to HIV pathogenesis
| Patient | Infection Type | HIV-1 Isolate (MT-2 tropism) | Follow-up (mo)* | Rate of CD4+ Decline† | CD4+ No | Anti-HIV Therapy | STD | HIV-1 RNA (No per mL) | CoR Usage | pcn/105 PBMCs | |||
| HIV-1 | HTLV-II | HIV-1 | HTLV-II | Ratio | |||||||||
| PR-1 | − | + (IIb) | — | 138 | None | 838 | — | — | — | — | Neg | 3216 | — |
| PR-2 | − | + (IIb) | — | 144 | None | 795 | — | — | — | — | Neg | 4627 | — |
| PR-3 | − | + (IIb) | — | 152 | None | 906 | — | — | — | — | Neg | 7375 | — |
| PR-4 | + | − | NSI | 96 | − 3.3 | 525 | None | A1 | 8600 | CCR5 | 1449 | Neg | — |
| PR-5 | + | − | NSI | 141 | − 3.4 | 242 | None | B2 | 40 190 | CCR5 | 1009 | Neg | — |
| PR-6 | + | − | NSI | 131 | − 2.7 | 520 | None | A1 | 40 000 | CCR5 | 931 | Neg | — |
| PR-7 | + | + (IIa) | NSI | 128 | − 3.2 | 384 | Zdv | C3 | 18 700 | CCR5 | 9760 | 240 | 40.6 |
| 302 | ddI‡ | C3 | 46 033 | CCR5 | 12 050 | <10 | >1200 | ||||||
| PR-8 | + | + (?) | ND | 159 | − 3.3 | 173 | 3tc/d4t/rtv | B3 | 286 | CCR5 | 7998 | <10 | >800 |
| PR-9 | + | + (IIb) | NSI | 132 | − 3.1 | 345 | None | A2 | 4457 | CCR5 | 1147 | 882 | 1.3 |
| PR-10 | + | + (IIb) | NSI | 136 | − 1.3 | 297 | None | B2 | 4266 | ND | 7698 | 6950 | 1.1 |
| PR-11 | + | + (IIa) | NSI | 141 | − 2.1 | 426 | None | B3 | 4810 | ND | 1844 | 16 239 | 0.11 |
| 330 | zdv + ddI | C3 | 36 530 | CCR51-153 (CXCR4) | 1060 | 500 | 2.1 | ||||||
| PR-12 | + | + (IIb) | NSI | 156 | + 0.1 | 1368 | None | A1 | <50 | ND | 640 | 13 397 | 0.05 |
| Patient | Infection Type | HIV-1 Isolate (MT-2 tropism) | Follow-up (mo)* | Rate of CD4+ Decline† | CD4+ No | Anti-HIV Therapy | STD | HIV-1 RNA (No per mL) | CoR Usage | pcn/105 PBMCs | |||
| HIV-1 | HTLV-II | HIV-1 | HTLV-II | Ratio | |||||||||
| PR-1 | − | + (IIb) | — | 138 | None | 838 | — | — | — | — | Neg | 3216 | — |
| PR-2 | − | + (IIb) | — | 144 | None | 795 | — | — | — | — | Neg | 4627 | — |
| PR-3 | − | + (IIb) | — | 152 | None | 906 | — | — | — | — | Neg | 7375 | — |
| PR-4 | + | − | NSI | 96 | − 3.3 | 525 | None | A1 | 8600 | CCR5 | 1449 | Neg | — |
| PR-5 | + | − | NSI | 141 | − 3.4 | 242 | None | B2 | 40 190 | CCR5 | 1009 | Neg | — |
| PR-6 | + | − | NSI | 131 | − 2.7 | 520 | None | A1 | 40 000 | CCR5 | 931 | Neg | — |
| PR-7 | + | + (IIa) | NSI | 128 | − 3.2 | 384 | Zdv | C3 | 18 700 | CCR5 | 9760 | 240 | 40.6 |
| 302 | ddI‡ | C3 | 46 033 | CCR5 | 12 050 | <10 | >1200 | ||||||
| PR-8 | + | + (?) | ND | 159 | − 3.3 | 173 | 3tc/d4t/rtv | B3 | 286 | CCR5 | 7998 | <10 | >800 |
| PR-9 | + | + (IIb) | NSI | 132 | − 3.1 | 345 | None | A2 | 4457 | CCR5 | 1147 | 882 | 1.3 |
| PR-10 | + | + (IIb) | NSI | 136 | − 1.3 | 297 | None | B2 | 4266 | ND | 7698 | 6950 | 1.1 |
| PR-11 | + | + (IIa) | NSI | 141 | − 2.1 | 426 | None | B3 | 4810 | ND | 1844 | 16 239 | 0.11 |
| 330 | zdv + ddI | C3 | 36 530 | CCR51-153 (CXCR4) | 1060 | 500 | 2.1 | ||||||
| PR-12 | + | + (IIb) | NSI | 156 | + 0.1 | 1368 | None | A1 | <50 | ND | 640 | 13 397 | 0.05 |
The data in the gray background are representative of the patient steady-state conditions at the time of PBMCs isolation.
pcn = proviral copies number; STD = stadiation; CoR = coreceptor; NSI = nonsyncytia-inducing phenotype; ND = not determined.
Following enrollment.
From Karlsson et al.28
Discontinued treatment: PR-7 since 1993, PR-11 since 1995.
CXCR4 usage emerged after a second passage onto PHA-stimulated blasts.